Summary
The role of epinephrine in platelet activation and the effect of an α2-adrenoceptor antagonist, midaglizole, during insulin-induced hypoglycaemia in Type 2 (noninsulin-dependent) diabetes mellitus were examined. The action of midaglizole as a platelet α2-antagonist was confirmed by in vitro studies using platelet-rich plasma and washed platelet suspension. Hypoglycaemia was induced by a bolus injection of short-acting insulin in 24 diabetic patients. They were divided into two groups, a control group (n=12) and an α2-group (n=12), and midaglizole was administered orally 60 min before insulin injection in the latter. Blood glucose and plasma C-peptide levels were significantly decreased (p<0.005) by insulin injection in both groups. Counter-regulatory hormones, including epinephrine, and arginine vasopressin were similarly increased at the hypoglycaemic nadir compared with the levels at 0 min in both groups. Plasma β-thromboglobulin was increased at the hypoglycaemic nadir (165.5±12.6ng/ml) compared with the level at 0 min (121.0±11.5, p<0.005) in the control group, whereas no significant increase was demonstrated in the α2 group. These results suggest that plasma epinephrine plays an important role in platelet activation during hypoglycaemia in Type 2 diabetes mellitus, and that the platelet activation is prevented by α2-adrenoceptor antagonist.
Article PDF
Similar content being viewed by others
References
Takeda H, Maeda H, Fukushima H, Nakamura N, Uzawa H (1981) Increased platelet phospholipase activity in diabetic subjects. Thromb Res 24: 131–141
Colwell JA, Winocour PD, Lopes-Virella M, Halushka PV (1983) New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med 75 (B): 67–80
Ishibashi T, Tanaka K, Taniguchi Y (1981) Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats. Diabetes 30: 601–606
Collier A, Tymkewycz P, Armstrong R, Young RJ, Jones RL, Clarke BF (1986) Increased platelet thromboxane receptor sensitivity in diabetic patients with proliferative retinopathy. Diabetologia 29: 471–474
Canny CLB, Kohner EM, Trautman J, Puklin J, Morse P (KROC Study Group, 1985) Comparison of stereofundus photographs in patients with insulin-dependent diabetes during conventional insulin treatment or continuous subcutaneous insulin infusion. Diabetes 34: 50–55
Dandona P, Bolger JP, Boag F, Fonesca V, Abrams JD (1985) Rapid development and progression of proliferative retinopathy after strict diabetic control. Br Med J 290: 895–896
Monnier LH, Lachkar H, Richard JL, Colette C, Borgel D, Orsetti A, Mirouze J (1984) Plasma β-thromboglobulin response to insulin-induced hypoglycemia in Type I diabetic patients. Diabetes 33: 907–909
Kishikawa H, Takeda H, Kiyota S, Sakakida M, Fukushima H, Ichinose K, Matsuda H, Nakamura N, Uzawa H (1987) Role of α2-adrenergic receptor in platelet activation during insulininduced hypoglycemia in normal subjects. Diabetes 36: 407–412
Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schinco P, Tamponi G, Emanuelli G (1986) Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 35: 818–825
Grant PJ, Stickland MH, Wiles PG, Davies JA, Wales JK, Prentice CRM (1987) Hormonal control of haemostasis during hypoglycemia in diabetes mellitus. Thromb Haemost 57: 341–344
Yamanaka K, Kigoshi S, Muramatsu I (1984) The selectivity of DG-5128 as an α2-adrenoceptor antagonist. Eur J Pharmacol 106: 625–628
Kashiwagi A, Harano Y, Suzuki M, Kojima H, Harada M, Nishio Y, Shigeta Y (1986) New α2-adrenergic blocker (DG-5128) improves insulin secretion and in vivo glucose disposal in NIDDM patients. Diabetes 35: 1085–1089
Kameda K, Ono S, Abiko Y (1982) Hypoglycemic action of 2-(2-(4,5-dihydro-1H-imidazole-2-yl)-1-phenylethyl)pyridine dihydrochloride sesquihydrate (DG-5128), a new hypoglycemic agent. Arzneim Forsch Drag Res 32: 39–44
Kawazu S, Suzuki M, Negishi K, Watanabe T, Ishii J (1987) Studies of midaglizole (DG-5128) — A new type of oral hypoglycemic drug in healthy subjects. Diabetes 36: 216–220
Lanza F, Cazenave JP (1985) Studies of alpha2-adrenergic receptors of intact and functional washed human platelets by binding of 3H-dihydroergocryptine and 3H-yohimbine-correlation of 3H-yohimbine binding with the potentiation by adrenaline of ADP-induced aggregation. Thromb Haemostas 54: 402–408
Beatty CH, Howard CFJr, Caruso V (1986) Potentiation with epinephrine of macaque platelet aggregation by other agonists: Implications for studies on human atherosclerosis. Thromb Res 41: 447–458
Lanza F, Cazenave JP, Beretz A, Sutter-Bay A, Kretz JG, Kieny R (1986) Potentiation by adrenaline of human platelet activation and the inhibition by the alpha-adrenergic antagonist nicergoline of platelet adhesion, secretion and aggregation. Agents Actions 18: 586–595
National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057
Siess W, Cuatrecasas P, Lapetina EG (1983) A role for cyclooxygenase products in the formation of phosphatidic acid in stimulated human platelets: differential mechanisms of action of thrombin and collagen. J Biol Chem 258: 4683–4686
Siess W, Weber PC, Lapetina EG (1984) Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-activating factor: epinephrine does not induce phospholipase C activation or platelet shape change. J Biol Chem 259: 8286–8292
Ysewijn-Van Brussel KARN, Deleenheer AP (1985) Development and evaluation of a radioimmunoassay for arg-vasopressin, after extraction with Sep-pak C18. Clin Chem 31: 861–863
Beyer TA, Hutson NJ (1986) Evidence for the role of the polyol pathway in the pathophysiology of diabetic complications. Metabolism 35 [Suppl. 1]: 1–3
Kennedy L, Baynes JW (1984) Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 26: 93–98
Hiramatsu K, Nozaki H, Arimori S (1987) Reduction of platelet aggregation induced by euglycaemic insulin clamp. Diabetologia 30: 310–313
Hilsted J, Madsbad S, Krarup T, Sestoft L, Christensen NJ, Tronier B, Galbo H (1981) Hormonal, metabolic, and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes 30: 626–633
Hoeldtke RD, Boden G, Shuman CR, Owen OE (1982) Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Int Med 96: 459–462
Abrahm DR, Hollingsworth PJ, Smith CB, Jim L, Zucker LB, Sobotka PA, Vinik AI (1986) Decreased α2-adrenergic receptors on platelet membranes from diabetic patients with autonomic neuropathy and orthostatic hypotension. J Clin Endocrinol Metab 63: 906–912
Spalding RM, Ward WK, Malpass TW, Stratton IR, Halter JB, Porte D Jr, Pfeifer MA (1986) Decreased numbers of platelet α-adrenergic binding sites in diabetes mellitus. Diabetes Care 9: 276–278
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takeda, H., Kishikawa, H., Shinohara, M. et al. Effect of α2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31, 657–663 (1988). https://doi.org/10.1007/BF00278748
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00278748